VVOS
Vivos Therapeutics Inc
NASDAQ: VVOS · HEALTHCARE · MEDICAL DEVICES
$0.80
+2.26% today
Updated 2026-04-30
Market cap
$11.46M
P/E ratio
—
P/S ratio
0.66x
EPS (TTM)
$-2.07
Dividend yield
—
52W range
$1 – $8
Volume
0.2M
Vivos Therapeutics Inc (VVOS) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3.79M | $11.39M | $13.07M | $16.89M | $16.02M | $13.80M | $15.03M | $17.44M |
| Revenue growth (YoY) | — | +200.4% | +14.7% | +29.2% | -5.1% | -13.9% | +8.9% | +16.0% |
| Cost of revenue | $1.08M | $2.74M | $2.65M | $4.28M | $6.00M | $5.53M | $6.01M | $6.90M |
| Gross profit | $2.71M | $8.66M | $10.41M | $12.60M | $10.02M | $8.27M | $9.02M | $10.54M |
| Gross margin | 71.5% | 76.0% | 79.7% | 74.6% | 62.5% | 59.9% | 60.0% | 60.4% |
| R&D | — | — | — | — | $200000.00 | $100000.00 | $100000.00 | — |
| SG&A | $9.27M | $16.17M | $16.09M | $25.79M | $29.04M | $22.48M | $17.88M | $27.73M |
| Operating income | $-8.34M | $-10.58M | $-12.04M | $-19.47M | $-25.03M | $-17.30M | $-11.17M | $-19.89M |
| Operating margin | -219.8% | -92.8% | -92.1% | -115.3% | -156.2% | -125.3% | -74.3% | -114.1% |
| EBITDA | $-7.73M | $-9.87M | $-11.24M | $-19.54M | $-24.36M | $-16.68M | $-10.59M | $-18.59M |
| EBITDA margin | -203.7% | -86.6% | -86.0% | -115.7% | -152.0% | -120.8% | -70.5% | -106.5% |
| EBIT | $-8.34M | $-10.62M | $-11.96M | $-20.27M | $-25.03M | $-17.30M | $-11.17M | $-19.89M |
| Interest expense | $102974.00 | $137876.00 | $96681.00 | $14000.00 | $1.19M | — | — | — |
| Income tax | — | — | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-8.44M | $-10.75M | $-12.06M | $-20.29M | $-23.84M | $-13.58M | $-11.14M | $-21.23M |
| Net income growth (YoY) | — | -27.4% | -12.1% | -68.3% | -17.5% | +43.0% | +18.0% | -90.6% |
| Profit margin | -222.5% | -94.4% | -92.3% | -120.2% | -148.8% | -98.4% | -74.1% | -121.7% |